Opexa Therapeutics was founded in 2003 and is based in The Woodlands, Texas. Opexa Therapeutics, Inc. operates as a biopharmaceutical company, developing autologous cellular therapies with the potential to treat major illnesses, including multiple sclerosis (MS) and diabetes. These therapies are based on Opexa's proprietary T-cell and adult stem cell technologies. The company's products include a T-cell therapeutic vaccine, Tovaxin, which is in clinical development for the treatment of MS. The adult stem cell technology is in the preclinical development stage. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006.

Fibrocell Science, Inc., a biotechnology company, focuses on developing regenerative fibroblast cells for aesthetic, medical, and scientific applications. The company is developing Azfibrocel-T, an investigational autologous cell therapy to treat nasolabial fold wrinkles. It was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. The company is based in Exton, Pennsylvania.

MorphoSys is a biotechnology firm with a human touch. Using its proprietary HuCAL catalog of fully human antibodies, the company is helping the world's largest drug firms develop human antibody therapies for a wide range of diseases. It helps its pharmaceutical clients in a number of ways: one, by installing its HuCAL library and related technology at customer sites in return for licensing fees; and second, by working in partnership with drug firms to develop potential antibody therapies. Its client list is a Who's Who of Big Pharma and includes Novartis, Pfizer, Roche, and Merck. MorphoSys also makes human antibodies (under the brand name AbD-Serotec) and sells them to researchers.

Axcan Pharma Inc. company develops and sells drugs mainly to treat gastrointestinal ailments. Its Urso line treats chronic liver disease, while two of its products (Canasa and Salofalk) offer relief for inflammatory bowel diseases. Axcan's Ultrase and Viokase are digestive aids for patients with exocrine pancreatic insufficiency, a condition associated with cystic fibrosis. The firm also owns the global rights to Photofrin, a photodynamic drug developed by QLT with applications for esophageal, gastric, and lung cancers. Other products include ulcer and diarrhea treatments, as well as chewable multivitamins. Axcan was acquired by TPG Capital for $1.3 billion in early 2008.

Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and changed its name to Fluidigm Corporation in June 2001. The company is based in San Francisco, California. Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis.

Bionovo, Inc. company was founded in 2002 and is based in Emeryville, California. Bionovo, Inc. is a clinical stage drug discovery and development company focusing on women’s health and cancer. The Company designs drugs derived from botanical sources, which have mechanisms of action. The Company’s drug candidate, Menerba, represents a class of receptor sub-type selective estrogen receptor modulator (SERM) for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to selectively modulate estrogen receptor beta (ERβ). In preclinical studies, Menerba inhibited tumor growth, as well as bone resorption known to cause osteoporosis, which is developed during menopause. The Company was developing BZL101, an oral anti-cancer agent for advanced breast cancer during the year ended December 31, 2008. BZL101 is designed to take advantage of the metabolism of cancer cells. BZL101 inhibits glycolysis, a metabolic pathway on which cancer cells rely.

Sangamo BioSciences, Inc. was founded in 1995 and is based in Richmond, California. Sangamo BioSciences, Inc. engages in the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs can be engineered to make ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off; and ZFP nucleases, proteins that enable to modify DNA sequences in various ways. The company’s ZFP Therapeutic, SB-509, a plasmid formulation of a ZFP TF activator of the vascular endothelial growth factor-A (VEGF-A) gene, which is in three Phase 2 clinical trials for the treatment of diabetic neuropathy and one Phase 2 trial for amyotrophic lateral sclerosis. It also develops SB-728-T, which is in the Phase 1 clinical trial for the treatment of HIV/AIDS. In addition, Sangamo BioSciences, Inc. involves in the preclinical development programs of ZFP therapeutics that focus on spinal cord injury, stroke, traumatic brain injury, neuropathic pain, and Parkinson's disease. Additionally, the company has research-stage programs in X-linked severe combined immunodeficiency, hemophilia, and hemoglobinopathies. It has license agreements with companies, including Dow AgroSciences, LLC;Sigma-Aldrich Corporation; Pfizer, Inc.; Genentech Inc.; and Medarex, Inc., as well as has research agreements with Amgen Inc., Novo Nordisk Inc., Novartis A/G, and Kirin Brewery Company.

Oncolytics Biotech is bringing in viral mercenaries to fight in the battle against cancer. The company is developing REOLYSIN, a therapy that utilizes a Respiratory Enteric Orphan virus (or reovirus) to treat a variety of advanced cancer tumors, both alone and in combination with other drug therapies, as well as radiation and chemotherapy. The Canadian company is collaborating with the US-based National Cancer Institute to conduct clinical trials of the treatment. It also conducts trials in Canada and the UK. Oncolytics' technologies are based on discoveries made by the Department of Microbiology and Infectious Diseases at the University of Calgary.

GlaxoSmithKline Pharmaceuticals (GSK India) is the top of the pill heap. India's leading pharmaceutical manufacturer, the company makes pharmaceuticals and consumer health care products through its two manufacturing facilities in Nashik and Thane; it also has a clinical development center in Bangalore. Its products include those targeting problems with infections, gynecology, dermatology, diabetes, and the cardiovascular system. Top sellers are Augmentin, Zinetac, Calpol, Phexin, and Betnesol. GSK India also makes vaccines to treat or prevent hepatitis A and B, the flu, chickenpox, and tetanus. Its distribution network stretches throughout the country. UK-based drugmaker GlaxoSmithKline owns GSK India.

Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, rheumatology, anesthesia, and antidotes in the United States. The company's Ophthalmic Segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting. It also sells therapeutic products, such as antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers and other national account customers. In addition, this segment offers non-pharmaceutical products, including various artificial tear solutions, preservative-free lubricating ointments, eyelid cleansers, vitamin supplements, and contact lens accessories. The company's Hospital Drugs and Injectables Segment markets specialty injectable pharmaceutical products, including antidotes and anesthesia, as well as products used in the treatment of rheumatoid arthritis and pain management. It markets products to hospitals through wholesalers and other national account customers, as well as directly to medical specialists. The company's Biologics and Vaccines Segment markets adult Tetanus-Diphtheria vaccines directly to hospitals and physicians, as well as through wholesalers and national distributors. Its Contract Services Segment manufactures products for third party pharmaceutical and biotechnology customers. The company also markets and distributes vaccines purchased from outside sources. Its customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, and other pharmaceutical companies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.